About this site.

What this site is

Script Tirzepatide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide. Our content is editorial commentary on publicly available science — the published clinical trials, mechanistic studies, pharmacological characterisations, and safety analyses that make up the tirzepatide literature.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. We have no affiliation with any pharmaceutical manufacturer.

The word 'script' in the domain name reflects the editorial register of this site — a technical-specification reading of the dual-incretin-agonist literature — not a prescription service, a pharmacy, or any implication that tirzepatide is obtainable through this site. It is not. This site provides editorial commentary on published research.

Every quantitative claim on this site is cited to a specific study. The reference list is available at Tirzepatide references. The mechanism of action, the trial data, and the safety record are documented as what they are: findings from peer-reviewed research, attributed to the studies that produced them.

What this site is not

Script Tirzepatide is not:

• A clinic, telehealth platform, or healthcare provider
• A pharmacy or compounding pharmacy
• A prescription service
• A product vendor of any kind
• A source of medical advice

We do not have doctors, pharmacists, or clinical staff. We do not offer consultations, prescriptions, or treatment recommendations. If you are considering tirzepatide as a medical treatment, consult a licensed healthcare provider.

The 'Effects & Safety' page on this site describes what people report from clinical-trial participation and post-market experience (clearly labeled anecdotal, not clinical evidence) and summarises cited safety cautions from the peer-reviewed literature. It is editorial commentary. It is not medical guidance.

How this site works

Content on Script Tirzepatide is drawn from the published peer-reviewed literature — specifically the compound corpus of tirzepatide clinical trials, mechanistic studies, and pharmacological reviews. All citations are listed in the references section with DOIs and PubMed links where available.

The site is organised around the mechanism-pharmacology lens — the dual GIP/GLP-1 receptor agonism that distinguishes tirzepatide from earlier incretin drugs is foregrounded, with the glycaemic and weight efficacy data and the safety record following from that mechanistic foundation.

For questions about the research documented here, contact us via the contact page. For medical questions about tirzepatide — dosing, eligibility, interactions, contraindications — consult a licensed clinician.